Abstract Objective To study the efficacy and safety of the Jiang Tang Fang Long Jiao Nang (Hypoglycemic Anti-Deafness Capsule) in treating non-insulin dependent diabetes mellitus with hearing loss. Methods Two hundred ninety six patients with non-insulin dependent diabetes mellitus and hearing loss were ran• domly assigned to a treatment group（n=164, 208 ears）and a control group（n=132, 184 ears） . Patients in the treatment group were treated with the Jiang Tang Fang Long Jiao Nang and supplement herbal prepa• rations as indicated by traditional Chinese medicine dialectical assessment, while control patients re• ceived glibenclamide and conventional treatments for deafness. Hearing, fasting blood glucose（FBG） , post-prandial blood glucose（PBG） , 24 hour urine sugar, platelet function indices, blood superoxide dis• mutase（SOD）and lipid peroxides（LPO）levels, and symptom improvement were compared between the two groups. Results The rate of hearing improvement was 56.7% for the treatment group and 26.6% for the control. FBG, PBG and 24 hour urine sugar improved in both groups, but the last two were superior in the treatment group compared to the control. Symptoms improvement was also superior in the treatment group compared to the control. In patients receiving Jiang Tang Fang Long Jiao Nang treatment, platelet function indices, SOD and LPO were all improved, while only LOP improvement was noticed in control patients. No acute or long-term toxicity was demonstrated for the Jiang Tang Fang Long Jiao Nang in ani• mal tests. The Jiang Tang Fang Long Jiao Nang lowered blood glucose and serum triglycerides in a rat model of alloxan-induced diabetes. Conclusion The Jiang Tang Fang Long Jiao Nang is effective in im• proving hearing and diabetic indices in diabetic patients with deafness, without significant side effects.
Introduction
Treatment of sensorineural deafness associated with diabetes is difficult due to the lack of under• standing of its mechanisms. In previous papers [1] [2] , the authors have reported treating hearing loss in diabetic patients using the Jiang Tang Fang Long Jiao Nang（Hypoglycemic Anti-Deafness Capsule） . This paper summarizes some of the preliminary re• sults of clinical and animal studies on this herbal paration.
Clinical Trials
Original Article 1 Materials and Methods 1.1 Subjects: Two hundred ninety six cases（392 ears） of non-insulin dependent diabetes mellitus （NIDDM） with deafness were identified. Hearing loss in these cases was characterized as mild（n = 68） , moderate（n = 112） , moderately severe（n = 128） , severe（n = 56）and profound（n = 28）using the ISO Standard 1964. Hearing loss was unilateral in 216 and bilateral in 156 cases. The onset was sudden in 44 and gradual in 348 cases. The patients were randomly assigned to a treatment （n = 164, 208 ears）and a control group（n = 132, 184 ears） . There were 68 males and 96 females in the treatment group, and 64 males and 68 females in the control group. The average age was 51.7
（ranging from 36 to 71） years for the treatment group and 51.1(34 to 70) years for the control group. The average duration of hearing loss was 4.7 (ranging from 1 to 11) years for the treatment group and 4.4(1 to 10）years for the control group. Patients with histories of traumatic brain injury, toxic diseases, noise induced deafness, poisoning, etc., were not included in this study.
1.2 Diagnostic Criteria: The diagnosis of NIDDM was made in line with the World Health Organization standards. Traditional Chinese medicine（TCM）dialectical types were determined in accordance with the New Chinese Medicine Clinical Research Guiding Principles 3 .
Audiometric tests and platelet function as
• says: Hearing was tested using a Madsen OB 802 pure-tone audiometer and a Madsen ZO 72 MB acoustic impedance audiometer(Madsen Electron• ics, Denmark). Platelet adhesion was tested using the turbidimetric method and platelet aggregation using a TYXN-90 coagulometer(Tongyong Tech• nology Institute, Shanghai, China).
1.4 Blood superoxide dismutase(SOD) activity and lipid peroxides(LPO) tests: Centrifugal serum of fasting blood from the upper limb was taken and SOD activity and LPO content were determined using the xanthopterin enzymatic oxidation method and the thiobarbituric acid assay, respectively.
1.5 Blood and urine glucose tests: Fasting blood glucose （FBG） and 2 hour postprandial blood glucose（PBG）were determined using the glucose oxidase method. Total 24 hour urine sugar was measured. Blood and urine sugar were tested before and at two weeks after the initiation of treatment. 3.3 Glucose control: All three indices improved in both groups（P < 0.05） . Greater improvement was seen in patients in the treatment group for PBG and 24 hour urine sugar compared to those in the control group （P< 0.05） , while FBG improvement was similar between the two groups （P< 0.05） （Table 2） .
3.4 Improvement of symptoms: More patients in the treatment group reported various extents of im• provement of diabetic symptoms（e.g., polydipsia, polyuria, hunger, weight loss and weakness）than those in the control group （Table 3） .
3.5 Platelet function indices, SOD and LPO: In the treatment group, platelet adhesion rate, plate• let aggregation rate and LPO level were reduced af• ter treatment（P < 0.05） , while SOD activity in• creased（P <0.05） . In the control group, LPO level was decreased（P < 0.05）while the rest three indi• ces remained unchanged（P<0.05） （Table 4） .
Animal Studies
Animals: Animals used in the study included Kunming mice（18-22 g bath sexes） , young Wistar rats（80-120 g, both sexes） and adult Wistar rats （200-220 g, both sexes） .
Methods and Results

Acute Toxicity Test:
The LD50 was not reached at the maximum Jiang Tang Fang Long Jiao Nang dose used in Kunming mice, The maximum tolerated dose was determined using guidelines from the New Drug Approval Methods Table 4 Comparisons of platelet function, SOD and LPO （mean ±SD） the animal' s maximum tolerable volume（0.8 mt/ 20g） and concentration（0.75/mt） . Animal were observed for their activities, feeding and excretion over the next 7 days. Animals were sacrificed on Day 7 for examination of its internal organs. There was no animal death during the 7 day observation period. There was a 1.81 ± 1.33 g weight gain.
Animals showed healthy appearance, with normal response to stimulation and normal spontaneous activities including feeding and excretion. Upon autopsy, no abnormalities were noticed of vital organs including heart, liver, spleen, lungs, kidney, etc. The maximum tolerated dose was determined to be greater than 30 g/kg, about 245 folds of the dose used in patients. 2.2Long-term Toxicity Test: Healthy rats（80-120g, n = 80, equal number of males and females） were randomly divided into four groups（20 in each group） after a 7 day housebreak period. Animals in three groups received Jiang Tang Fang Long Jiao Nang suspension at a daily morning dose of 30 g/kg, 10 g/kg and 3.3 g/kg respectively, while those in the remaining group served as controls group and received equal volume of distilled water. Half of the animals in each group were sacrificed at 3 months for serum biochemical panel tests and histological examination of tissues from the heart, liver, kidney, spleen, adrenal gland, pancreas, small intestine and brain. Except for decreased blood urea nitrogen levels in animals receiving daily 30 g/kg Jiang Tang Fang Long Jiao Nang（P < 0.05） , all biochemical indices, white blood cell count/differentiation and body weight showed little or no difference（P< 0.05）before and after treatment and among all groups. Histological examination showed no signs of inflammation, atrophy, necrosis or any other pathological changes in sampled organs in all four groups.
2.3 Hypoglycemic and lipid-lowering effects: Following previously reported protocols 6 , 5% tetraoxypyrimidine （prepared with cold saline） was injected subcutaneously at 0.34 mt/100 g to male and female Wistar rats after the 1 week housebreak period. At 2 weeks, tail vein blood samples were collected while animals were anesthetized with intraperitoneal injection of 2% pentobarbital（0.2 mt/100 g） . Serum glucose levels were determined using glucose oxidase method, · · 48 Table 5 Glucose(GLU) and triglyceride changes (TG) （mean ± SD） * P ＜ 0.05, ** P ＜ 0.01, compared to pretreatment levels. # P ＜ 0.05, ## P ＜ 0.01, compared to the control.
and triglyceride levels using GPO enzymatic assay. Eighty animals whose glucose levels were at 22.2 mml/L or higher were selected to be treated with alloxan for induction of diabetes. Diabetic animals were then randomly divided into 4 groups to receive high dose Jiang Tang Fang Long Jiao Nang （25 g/kg） , low dose Jiang Tang Fang Long Jiao Nang （10 g/kg） , Yu Quan Wan （an herbal preparation containing kudzu vine root, tricosanthes kirilowii, rehmannia glutinosa, ophionogon japonicus and Fructus Schisandrae Chinensis） , or to serve as controls, respectively. Jiang Tang Fang Long Jiao Nang and Yu Quan Wan were mixed with the forage and orally fed to the animals. Animals in the control group were fed with normal forage with no medications. All animals had unrestricted access to drinking water. Tail vein blood was sampled under general anesthesia at 2 weeks for testing of glucose and triglyceride levels. Animals in the three treatment groups showed lower glucose levels compared to before treatment（P < 0.05） and to those in the control group（P < 0.05） . However, decrease of triglyceride levels was seen only in Jiang Tang Fang Long Jiao Nang -treated animals（P < 0.05） , but not in Yu Quan Wan-treated or non-treated animals. Deficiency, deafness and impaired vision" . Our clinical data suggest that the Jiang Tang Fang Long Jiao Nang can improve SOD levels, lower blood glucose, blood lipids and fibrinogen, improve platelet function indices, and improve hearing in NIDDM patients with hearing loss.
Discussion
Our animal study data indicate that the Jiang Tang Fang Long Jiao Nang is safe in both short and long term uses. The data also show that the Jiang Tang Fang Long Jiao Nang reduces blood glucose and serum triglyceride contents in
